Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas

NCT07217171 is registered in ClinicalTrials.gov with EvolveImmune United, Inc as lead sponsor.

NCT NCT07217171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07217171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas
Lead sponsor
EvolveImmune United, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
November 13, 2025
Completion date
January 29, 2031
Enrollment
160 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

anal squamous cell carcinoma, bladder cancer, cervical squamous cell carcinoma, cutaneous squamous cell cancer, esophageal squamous cell carcinoma, penile squamous cell carcinoma, squamous cell carcinoma of the lung, tongue squamous cell carcinoma, urethral squamous cell carcinoma, vaginal squamous cell carcinoma, vulvar squamous cell carcinoma